Making or losing money with participation in clinical trials: A decision analysis

Onkologie

Volumn 32, Issue 7, 2009, Pages 411-416

  Jacobs, Volker R ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Clinical study; Cost covering; Decision analysis; Economics; Flow chart; Model; Study management

Indexed keywords

ARTICLE; BUDGET; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FINANCIAL MANAGEMENT; HEALTH CARE COST; INCOME; MEDICAL DECISION MAKING; MEDICOLEGAL ASPECT;

CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; GERMANY; INCOME; MODELS, ECONOMIC; PATIENT SELECTION; PATIENTS;

EID: 68149179467     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218362     Document Type: Article

References (23)

1. Jacobs VR, Thoedtmann J, Brunner B, Kiechle M: An economic model to reduce the cost of chemotherapy for gynecologic cancer. Int J Fertil Wom-ens Med 2004;49:274-277.
2. Jacobs VR, Thödtmann J, Brunner B, Kiechle M: Modell eines aktiven Kostenmanagements gynäkoonkologischer Therapien zur Reduktion der Medikamentenkosten um 58,7% innerhalb eines Jahres. [Model of an active cost management of gyneco-oncological therapies for reduction of medication costs by 58.7% within one year.] Geburtshilfe Frauenheilkd 2005;65:46-55.
3. Jacobs VR, Thoedtmann J, Euler U, Paepke S, Fischer T, Harbeck N, Kiechle M: Physician-based active cost management of oncological therapies reducing pharmaceutical costs by 83.4% in two years without leaving standard of care. Onkologie 2005;28: 441-445.
4. Greco D, Diniz NM: Conflicts of interest in research involving human beings. J Int Bioethique 2008;19: 143-154,202-203.
5. Tereskerz PM: Research accountability and financial conflicts of interest in industry-sponsored clinical research: a review. Account Res 2003;10:137-158.
6. Tereskerz PM, Moreno J: Ten steps to developing a national agenda to address financial conflicts of interest in industry sponsored clinical research. Account Res 2005;12:139-155.
7. American Society of Clinical Oncology (ASCO): American Society of Clinical Oncology policy statement: oversight of clinical research. J Clin Oncol 2003;21:2377-2386.
8. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P: Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices - budget impact analysis. Value Health 2007;10:336-347.
9. Neumann PJ: Budget impact analysis gets some respect. Value Health 2007;10:324-325.
10. Fireman BH, Fehrenbacher L, Gruskin EP, Ray GT: Cost of care for patients in cancer clinical trials. J Natl Cancer Inst 2000;92:136-142.
11. Steurer J, Bachmann LM: Management eines Forschungsprojektes. [Managerial considerations in research]. Ther Umsch 2007;64:683-686.
12. Antman K: Reimbursement issues facing patients, providers, and payers. Cancer 1993;72(suppl 9):2842-2845.
13. Beal K, Dean J, Chen J, Dragaon E, Saulino A, Collard CD: Budget negotiation for industry-sponsored clinical trials. Anesth Analg 2004;99:173-176.
14. Jacobs VR: Das aktuelle Bundessozialgerichtsurteil zur Studienfinanzierung: Onkologische Studien in Deutschland vor dem finanziellen Ende? [The recent decision of the German Federal Social Court regarding funding of studies: will oncological studies in Germany be terminated for financial reasons?]. Onkologie 2004;27:589-590.
15. Krankenhausentgeltgesetz (KHEntgG) [Hospital Payment Law], www.g-drg.de/cms/index.php/inek-site-de/Rechtsgrundlagen/Gesetze-und-V erord-nungen/Krankenhausentgeltgesetz-KHEntgG (06.03.2009).
16. Jacobs VR: Cost planning for oncological therapies from the clinic's point of view regarding clinical care and studies. 1. COMBATing Breast Cancer Conference, Frankfurt, 21.-22. November 2008. Geburtshilfe Frauenheikd 2008;68:1226-1228.
17. Jacobs VR: Wirtschaftliche Durchführung von klinischen Studien aus Sicht der Universitäts-/Frauenklinik [Economic performance of clinical studies from the university/OB/GYN clinic perspective]; in Harbeck N (Hrsg): Das frühe Mammakarzinom. [Early Breast Cancer]. Bremen, Uni-Med Verlag, 2008, pp 114-119.
18. Münchner Studienzentrum [Munich Study Center], www.muenchner- studienzentrum.de (06.03.2009).
19. Wagner JL, Alberts SR, Sloan JA, Cha S, Killian J, O'Connell MJ, van Grevenhof P, Lindman J, Chute CG: Incremental costs of enrolling patients in clinical trials: a population-based study. J Natl Cancer Inst 1999;91:847-853.
20. Bennett CL, Stinson TJ, Vogel V, Robertson L, Leedy D, O'Brien P, Hobbs J, Sutton T, Ruckdeschel JC, Chirikos TN, Weiner RS, Ramsey MM, Wicha MS: Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project. J Clin Oncol 2000;18:2805-2810.
21. Bennett CL, Adams JR, Knox KS, Kelahan AM, Silver SM, Bailes JS: Clinical trials: are they a good buy? J Clin Oncol 2001;19:4330-4339.
22. Jacobs VR: Kostendeckende Durchführung von klinischen Studien. [Cost-covering performance of clinical studies]. German Breast Group (GBG), Annual Meeting 2009, February 19-20, Frankfurt, Germany.
23. Deutsche Gesellschaft für Senologie (DGS) [German Society for Senology]: Erhebungsbogen für Brustzentren: Anteil Studienpatienten, S. 14 [Survey for breast centers. Proportion of study patients, p. 14], www.senologie.org/download/word-fab-er-hebungsbogen-B1(31.08,2006).doc (06.03.2009).